[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surveillance-colonoscopy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surveillance-colonoscopy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100622077","ultra-high-risk-surveillance-to-avoid-future-events-the-ultra-safe-trial-100622077",false,"NCT07378930","ULTRA-high-risk Surveillance to Avoid Future Events: the ULTRA-SAFE Trial","ULTRA-SAFE","Inclusion Criteria:\n\n1. Age: Adults aged 40 to 75 years.\n2. Initial Colonoscopy Findings: Detection and removal of at least two advanced adenomas during the baseline colonoscopy.\n3. Adherence: Willingness to comply with the assigned screening protocol, including fecal immunochemical testing (FIT) and follow-up colonoscopies\n\nExclusion Criteria:\n\n1. Age: Individuals younger than 40 or older than 75 years.\n2. High-Risk Predispositions: Patients with inflammatory bowel disease (IBD), Familial Adenomatous Polyposis (FAP), or a documented hereditary colorectal cancer syndrome (e.g., Lynch syndrome).\n3. Cancer History: A history of colorectal cancer (excluding carcinoma in situ).\n4. Contraindications: Patients for whom polypectomy is clinically inappropriate or unsafe.\n5. Adenoma Count\u002FType: Failure to meet the requirement of at least two advanced adenomas during the initial colonoscopy.\n\n7.Extensive Low-Risk Lesions: Presence of more than ten low-risk adenomas.\n\n8.Pregnancy: Currently pregnant individuals.","ALL","40 Years","75 Years",{"count":20,"type":21},940,"ESTIMATED","INTERVENTIONAL",[24],"NA","The ULTRA-SAFE clinical trial is a prospective, randomized study designed to address the limitations of current \"one-size-fits-all\" colorectal cancer surveillance guidelines. While international standards recommend a three-year follow-up colonoscopy for all high-risk patients, data suggests that those with multiple advanced adenomas face a significantly higher recurrence risk (20%) compared to those with only low-risk adenomas (9%). To provide more personalized care, the trial compares a Standard Arm (colonoscopy at year three) against a FIT Arm, where participants undergo annual fecal immunochemical testing in years one and two. A positive FIT triggers an earlier colonoscopy, with the goal of reducing the 3-year prevalence of metachronous advanced colorectal neoplasms (meta-ACRN) from 20% to approximately 12.7%. The study has enrolled roughly 940 participants to statistically validate whether this early screening intervention can effectively prevent future malignant events in ultra-high-risk populations.",[27,28,29],"Colorectal Neoplasms","Colorectal Cancer Prevention","Surveillance Colonoscopy",[31,32,33,34],"Colonoscopy surveillance","Colorectal cancer prevention","Post-polypectomy surveillance","Fecal immunochemical test","NOT_YET_RECRUITING","2026-01-23",{"date":38,"type":39},"2026-01-30","ACTUAL",{"date":41,"type":21},"2026-03-01",{"date":43,"type":21},"2031-05-01",{"name":45,"class":46},"National Taiwan University Hospital","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100559775","study-to-evaluate-the-diagnostic-performance-of-of-magentiq-colo-during-colonoscopy-100559775","NCT06568523","Study to Evaluate the Diagnostic Performance of of MAGENTIQ-COLO During Colonoscopy.","A Multicenter Study to Evaluate the Diagnostic Performance of Computer-aided Polyp Size Classification of the MAGENTIQ-COLO During Real-time Colonoscopy","Inclusion Criteria:\n\n* Individuals aged ≥45 - ≤80 years old, who are scheduled for non-iFOBT screening or surveillance colonoscopy.\n\nExclusion Criteria:\n\n1. In situ polyps with known histology detected in a previous colonoscopy.\n2. No colorectal polyps detected during colonoscopy.\n3. Known or suspected inflammatory bowel disease.\n4. Polyposis syndrome (e.g., familial adenomatous polyposis, serrated polyposis).\n5. Non-hereditary polyposis syndromes (e.g. Lynch syndrome).\n6. History of chemotherapy or radiation therapy for colorectal lesions.\n7. Pregnancy.\n8. Has a referral for therapeutic procedure (i.e., endoscopic mucosal resection, intervention to stop a lower gastro-intestinal bleeding, etc.).\n9. Inability to undergo polypectomy (e.g., incorrect continued use of anticoagulants, comorbidities) or patient refusal, as assessed by the endoscopist.\n10. Inability to provide informed consent.",true,"45 Years","80 Years",{"count":58,"type":21},330,[24],"This is an international, multicenter, study to evaluate the diagnostic performance of the CADx polyp sizing modality of the MAGENTIQ-COLO.",[62,29],"Screening Colonoscopy",[27,64,65,62,29,66],"Intestinal Neoplasms","Digestive System Neoplasms","Automatic Polyp Detection","2024-08-21",{"date":69,"type":39},"2024-08-23",{"date":71,"type":21},"2024-09-15",{"date":73,"type":21},"2025-08-31",{"name":75,"class":76},"Magentiq Eye LTD","INDUSTRY",5]